Dajsakdipon T, Susiriwatananont T, Wongkraisri C, Ithimakin S, et al. Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand. BMC Cancer 2024;24:1018.
PMID: 39152401